SEATTLE -- Availability of a bevacizumab (Avastin) biosimilar for ophthalmic use could have the unintended consequence of driving up the cost of treating retinal disease with angiogenesis inhibitors, ...
MedPage Today on MSN
Better survival in refractory CRC with chemo plus bevacizumab, real-world study says
OS of 8.9 months versus 5.8 months with trifluridine/tipiracil alone, supporting phase III ...
On April 10, 2025, Biocon Biologics Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved JOBEVNE™ (bevacizumab-nwgd), a new bevacizumab biosimilar referencing Genentech’s ...
Please provide your email address to receive an email when new articles are posted on . Researchers observed reduced risk for disease progression and death with the investigative combination.
Bevacizumab (Avastin, Roche [originator] and biosimilars) with fluoropyrimidine-based chemotherapy is indicated for the 'treatment of adult patients with metastatic carcinoma of the colon or rectum'.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results